Ongoing Projects
GNR-055
We are working in partnership with Generium to trial GNR-055, a recombinant fusion protein specifically designed for treating mucopolysaccharidosis II (MPS II, Hunter syndrome). Generium is conducting clinical trials in Russia, and Actigen is preparing for clinical trials in other selected markets.
Generium has initiated clinical trials, currently in Phase 2 in the Russian Federation. Actigen is currently planning to initiate clinical trials.